Satiety Enhancement Strategies
Using peptides to improve feelings of fullness and reduce overall caloric intake.
Introduction
Satiety, the fullness that ends a meal, has strong human evidence only for the GLP-1 and amylin drugs. Hunger hormones are covered in hunger hormone modulation and the appetite regulation overview.
Satiety-Enhancing Peptides
Primary Options
| Peptide | Satiety Effect | Mechanism | Evidence |
|---|---|---|---|
| Semaglutide | Very strong | GLP-1 pathway | Approved |
| Tirzepatide | Very strong | GLP-1 and GIP | Approved |
| Melanotan II | Unclear | MC4R activation | Side effect in a 1998 trial of 10 men |
| Tesamorelin | None shown | GH-mediated | Label: not for weight loss |
| CJC-1295 | None shown | Indirect via GH | No data |
As of October 2026, the approved options are prescription medicines. FDA approved tirzepatide (Zepbound) for weight management in November 2023. The Wegovy pill (oral semaglutide 25 mg daily) followed in December 2025, and Wegovy HD (7.2 mg weekly) in March 2026. Research-use vials aren't equivalent to these products (see our semaglutide profile).
Mechanism Details
| Pathway | Effect on Satiety | Peptides Involved |
|---|---|---|
| Melanocortin | Central appetite suppression | Melanotan II |
| GLP-1 | Gastric slowing, central effects | Incretin mimetics |
| Amylin | Gastric slowing | Cagrilintide |
| GH/IGF-1 | None shown | Most GH peptides |
Practical Implementation
Timing for Satiety
Pre-meal dosing 30-60 min before meals comes from user guides; no trial has tested it.
Combination Approaches
| Primary | Support | What's known |
|---|---|---|
| Semaglutide | Cagrilintide | CagriSema: 20.4% weight loss at 68 weeks (Phase 3) |
| Ipamorelin | Melanotan II | Untested |
| Fragment 176-191 | Neutral appetite | Not a satiety agent |
CagriSema was filed with FDA in December 2025 and, as of October 2026, isn't approved. AOD-9604, a modified hGH 176-191 fragment, missed its 12-week weight-loss endpoint in a 536-person oral trial; FDA's December 2024 review found it failed to beat placebo in most human studies.
Dietary Synergies
High protein and fiber add fullness on their own. Trial participants on Wegovy and Zepbound also dieted and exercised.
Managing Hunger During Cuts
Advice for evening hunger or carb cravings is untested. Users widely report intense hunger on GHRP-6.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- FDA approves Zepbound (tirzepatide) for chronic weight management (FDA, 2023)
- FDA approves oral Wegovy pill; OASIS 4 results (Novo Nordisk, 2025)
- FDA approves higher-dose semaglutide, Wegovy HD 7.2 mg (FDA, 2026)
- Novo Nordisk files CagriSema with the FDA; REDEFINE 1 results (Novo Nordisk, 2025)
- FDA briefing document on AOD-9604, Pharmacy Compounding Advisory Committee (FDA, 2024)
- Egrifta WR (tesamorelin) prescribing information (FDA, 2025)
- Melanotan-II in men with psychogenic erectile dysfunction, crossover trial (Journal of Urology, 1998)